Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene
- PMID: 3684597
- PMCID: PMC306474
- DOI: 10.1093/nar/15.22.9365
Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene
Abstract
We have investigated the structural gene for adenosine deaminase (ADA) in a female infant with ADA deficiency associated severe combined immune deficiency (ADA-SCID) disease and her family by DNA restriction-fragment-length analysis. In this family a new ADA-specific restriction-fragment-length variant was detected, which involves a 3.2-kb deletion spanning the ADA promoter as well as the first exon. It was found that the patient, who was born to a consanguineous couple, was homozygous and both her parents and her brother were heterozygous for the deletion. No ADA-specific mRNA could be detected by hybridization in fibroblasts derived from this patient. Thus the patient was established to be homozygous for a true null ADA allele. In the light of the apparently normal development of most tissues except the lymphoid tissue the above finding directly questions the classification of ADA as a 'housekeeping' enzyme.
Similar articles
-
Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency.J Immunol. 1987 May 15;138(10):3203-6. J Immunol. 1987. PMID: 3571974
-
Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.J Clin Invest. 1988 May;81(5):1323-7. doi: 10.1172/JCI113458. J Clin Invest. 1988. PMID: 3366897 Free PMC article.
-
Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.Nucleic Acids Res. 1984 Jan 25;12(2):1015-24. doi: 10.1093/nar/12.2.1015. Nucleic Acids Res. 1984. PMID: 6198631 Free PMC article.
-
Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency.Ciba Found Symp. 1978;(68):213-30. doi: 10.1002/9780470720516.ch14. Ciba Found Symp. 1978. PMID: 227649 Review.
-
Complete and partial adenosine deaminase deficiency. Relationship of immune function to metabolite concentrations, enzyme activity, and effects of therapy.Ann N Y Acad Sci. 1985;451:20-5. doi: 10.1111/j.1749-6632.1985.tb27092.x. Ann N Y Acad Sci. 1985. PMID: 3907453 Review. No abstract available.
Cited by
-
Molecular analysis of two mouse dilute locus deletion mutations: spontaneous dilute lethal20J and radiation-induced dilute prenatal lethal Aa2 alleles.Mol Cell Biol. 1990 Feb;10(2):501-9. doi: 10.1128/mcb.10.2.501-509.1990. Mol Cell Biol. 1990. PMID: 2300051 Free PMC article.
-
Prospects for homologous recombination in human gene therapy.Hum Genet. 1991 Jul;87(3):245-53. doi: 10.1007/BF00200899. Hum Genet. 1991. PMID: 1864597 Review.
-
Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells.Nucleic Acids Res. 1993 Dec 25;21(25):5890-5. doi: 10.1093/nar/21.25.5890. Nucleic Acids Res. 1993. PMID: 8290349 Free PMC article.
-
Adenosine deaminase gene expression is regulated posttranscriptionally in the nucleus.Nucleic Acids Res. 1988 Apr 25;16(8):3255-68. doi: 10.1093/nar/16.8.3255. Nucleic Acids Res. 1988. PMID: 3163799 Free PMC article.
-
A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.Am J Hum Genet. 1989 Sep;45(3):354-61. Am J Hum Genet. 1989. PMID: 2773932 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials